The TEL/ARG Leukemia Oncogene Promotes Viability and Hyperresponsiveness to Hematopoietic Growth Factors

International Journal of Hematology

Volumn 79, Issue 2, 2004, Pages 138-146

  Okuda, Keiko ^a   Sato, Yuko ^b   Sonoda, Yoshiaki ^a   Griffin, James D ^c,d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chimeric oncogene; Leukemia; Signal transduction; TEL ARG; Tyrosine kinase

Indexed keywords

CBL PROTEIN; CELL PROTEIN; COMPLEMENTARY DNA; DOXYCYCLINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEMOPOIETIC GROWTH FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN DOK; PROTEIN SHC; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SOMATOMEDIN C; STAT5 PROTEIN; TEL ARG PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL DEATH; CELL GROWTH; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUSION; GROWTH RATE; LEUKEMOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TEL ARG ONCOGENE;

EID: 1442334989     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.03125     Document Type: Article

References (48)

1. Kruh GD, King CR, Kraus MH, et al. A novel human gene closely related to the abl proto-oncogene. Science. 1986;234:1545-1548.
2. Kruh GD, Perego R, Miki T, Aaronson SA. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl Acad Sci U S A. 1990;87:5802-5806.
3. Perego R, Ron D, Kruh GD. Arg encodes a widely expressed 145-kDa protein-tyrosine kinase. Oncogene. 1991;6:1899-1902.
4. Koleske AJ, Gifford AM, Scott ML, et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron. 1998;21:1259-1272.
5. Cazzaniga G, Tosi S, Aloisi A, et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a 1(1; 12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood. 1999;94:4370-4373.
6. Iijima Y, Ito T, Oikawa T, et al. A new ETV6/TEL partner gene ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25; p13) translocation. Blood. 2000;95:2126-2131.
7. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995;92:4917-4921.
8. Golub TR, Barker G, Lovett M, Gilliland DG. Fusion of platelet-derived growth factor beta to a novel ets-like gene in chronic myelomonocytic leukemia with 1(5;12) chromosomal translocation. Cell. 1994;77:307-316.
9. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850.
10. Papadopoulos P, Ridge SA, Boucher DA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 1995;55:34-38.
11. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996;16:4107-4116.
12. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
13. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
14. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
15. Eguchi M, Eguchi-Ishimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12; 15)(013;q25). Blood. 1999;93:1355-1363.
16. Liu Q, Schwaller J, Kutok J, et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12; 15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 2000;19:1827-1838.
17. Kuno Y, Abe A, Emi N, et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood. 2001;97:1050-1055.
18. Yagasaki F, Wakao D, Yokoyama Y, et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p 16;p13) chromosomal translocation. Cancer Research. 2001;61:8371-8374.
19. Iijima Y, Okuda K, Tri NK, et al. Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG. Oncogene. 2002;21:4374-4383.
20. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
21. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
22. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;15:2440-2448.
23. Palacios R, Steinmetz M. IL-3-dependent mouse clones that express B-220 surface antigen, contain 1g genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41:727-734.
24. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998;91:3927-3934.
25. Okuda K, Golub TR, Gilliland DG, Griffin JD, P210BCR/ABL. p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996;13:1147-1152.
26. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T. Griffin JD. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992;79:2215-2220.
27. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811-820.
28. Salgia R, Li J, Lo SH, et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by p210(bcr/abl). J Biol Chem. 1995;270:5039-5047.
29. Matsuguchi T, Salgia R, Hallek M, et al. Shc phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and Steel Factor, and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994;269:5016-5021.
30. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269:22925-22928.
31. Hallek M, Danhauser-Riedl S, Herbst R, et al. Interaction of the receptor tyrosine kinase p145 c-kit with the p210 bcr/abl kinase in myeloid cells. Br J Haematol. 1996;94:5-16.
32. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996;98:521-528.
33. Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997;100:46-57.
34. Okuda K, D'Andrea A, Van Etten RA, Griffin JD. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. J Clin Invest. 1997;100:1708-1715.
35. Woodring PJ, Litwack ED, O'Leary DDM, Lucero GR, Wang JYJ, Hunter T. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol. 2002;156:879-892.
36. Kharbanda S, Pandey P, Jin S, et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997;386:732-735.
37. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806-809.
38. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/ abl hybrid gene. Science. 1986;233:212-214.
39. Griesinger F, Janke A, Podleschny M, Bohlander SK. Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br J Haematol. 2002;119:454-458.
40. Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood. 1992;80:1788-1797.
41. Carlesso N, Griffin JD, Druker BJ. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR/ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 1994;9:149-156.
42. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science. 1992;256:836-839.
43. Wang B, Kruh GD. Subcellular localization of the Arg protein tyrosine kinase. Oncogene. 1996;13:193-197.
44. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 2000;96:2277-2283.
45. Yamanashi Y, Baltimore D. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell. 1997;88:205-211.
46. Noguchi T, Matozaki T, Inagaki K, et al. Tyrosine phosphorylation of p62 (Dok) induced by cell adhesion and insulin: possible role in cell migration. EMBO J. 1999;18:1748-1760.
47. Carroll M, Ohno-Jones S, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
48. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.